09.28.15
ADMA Biologics Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases , said the company has been recognized as one of the 50 fastest growing companies in New Jersey by NJBIZ, a New Jersey-focused weekly business news publication.
"ADMA Biologics is honored to be recognized as one of the fastest growing companies in New Jersey, and we extend our congratulations to the other honorees," said Adam Grossman, president and chief executive officer, ADMA Biologics. "We are proud of the rapid evolution of our company, and this distinction is a tremendous honor as we look towards the future. At ADMA Biologics, our mission is to offer treatment options to immune-compromised patients, and we remain committed to fulfilling that mission."
In the past three years, ADMA Biologics has accomplished numerous milestones. These milestones include significant year over year revenue growth, completion of an initial public offering with an uplisting to the Nasdaq, completion of a Phase III clinical study with positive results, and the submission of a Biologics License Application to the
U.S. Food and Drug Administration . Additionally, ADMA Biologics has secured intellectual property for its lead product candidate which extends to January 2035 and continues to build its New Jersey based commercialization team in preparation for a potential launch of RI-002 during the second half of 2016.
The NJBIZ 50 Fastest Growing Companies awards program celebrates New Jersey's most dynamic companies who progressively contribute to the success of the state's economic growth and stability . To qualify, companies had to meet selection criteria that included a revenue size of at least $500,000 within the past two out of three years and growth in revenue over a three year period, dating from fiscal year 2012 to 2014.
For more information about the NJBIZ 50 Fastest Growing Companies awards program visit www.njbiz.com/events.
"ADMA Biologics is honored to be recognized as one of the fastest growing companies in New Jersey, and we extend our congratulations to the other honorees," said Adam Grossman, president and chief executive officer, ADMA Biologics. "We are proud of the rapid evolution of our company, and this distinction is a tremendous honor as we look towards the future. At ADMA Biologics, our mission is to offer treatment options to immune-compromised patients, and we remain committed to fulfilling that mission."
In the past three years, ADMA Biologics has accomplished numerous milestones. These milestones include significant year over year revenue growth, completion of an initial public offering with an uplisting to the Nasdaq, completion of a Phase III clinical study with positive results, and the submission of a Biologics License Application to the
U.S. Food and Drug Administration . Additionally, ADMA Biologics has secured intellectual property for its lead product candidate which extends to January 2035 and continues to build its New Jersey based commercialization team in preparation for a potential launch of RI-002 during the second half of 2016.
The NJBIZ 50 Fastest Growing Companies awards program celebrates New Jersey's most dynamic companies who progressively contribute to the success of the state's economic growth and stability . To qualify, companies had to meet selection criteria that included a revenue size of at least $500,000 within the past two out of three years and growth in revenue over a three year period, dating from fiscal year 2012 to 2014.
For more information about the NJBIZ 50 Fastest Growing Companies awards program visit www.njbiz.com/events.
